REGISTERED NUMBER: 13811276 (England and Wales)

Financial Statements for the Year Ended 31 March 2025

for

Ultrahuman Healthcare Ltd

Page

Balance Sheet

1

Notes to the Financial Statements

2

CURRENT ASSETS

Stocks

610,478

411,666

Debtors

4

544,309

95,266

Cash at bank

1,590,747

185,843

2,745,534

692,775

CREDITORS

Amounts falling due within one year

5

(3,106,395

)

(557,094

)

NET CURRENT (LIABILITIES)/ASSETS

(360,861

)

135,681

TOTAL ASSETS LESS CURRENT LIABILITIES

(360,861

)

135,681

CREDITORS

Amounts falling due after more than one year

6

(200,000

)

(200,000

)

NET LIABILITIES

(560,861

)

(64,319

)

CAPITAL AND RESERVES

Called up share capital

7

1,000

1,000

Other reserves

769

-

Retained earnings

(562,630

)

(65,319

)

SHAREHOLDERS' FUNDS

(560,861

)

(64,319

)

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 5 December 2025 and were signed on its behalf by:

M Kumar - Director

1.	STATUTORY INFORMATION

Ultrahuman Healthcare Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number:

13811276

Registered office:

5 New Street Square

London

EC4A 3TW

The presentation currency of the financial statements is the Pound Sterling (£).

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going concern

At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

Turnover

Revenue is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax

Stocks

Inventories are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the average costing method. The carrying amount of inventory sold is recognised as an expense in the period in which the related revenue is recognised.

Cash and cash equivalents

Cash and cash equivalents in the statement of financial position comprise cash at banks and in hand, short term deposits with an original maturity date of one month. Cash equivalents are defined as short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value

Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 3 (2024 - 2 ) .

4.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.3.25

31.3.24

£

£

Trade debtors

226,384

6,577

Amounts owed by group undertakings

143,291

-

Other debtors

174,634

88,689

544,309

95,266

5.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.3.25

31.3.24

£

£

Trade creditors

998,474

500,204

Amounts owed to group undertakings

1,466,942

50,187

Taxation and social security

246,261

-

Other creditors

394,718

6,703

3,106,395

557,094

6.

CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

31.3.25

31.3.24

£

£

Other creditors

200,000

200,000

7.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

31.3.25

31.3.24

value:

£

£

1,000

Ordinary

£1

1,000

1,000

8.	DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Sadikali Premji (Senior Statutory Auditor)

for and on behalf of TC Group

9.	RELATED PARTY DISCLOSURES

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

10.	POST BALANCE SHEET EVENTS

On 22 August 2025, the company completed the acquisition of 100% of the issued share capital of Vio HealthTech Limited, a company registered in England and wales under registration number 05546719.

Following the acquisition, Vio HealthTech Limited became a wholly owned subsidiary of Ultrahuman Healthcare Ltd.

This transaction took place after the balance sheet date and therefore has no impact on the financial position reported at that date.

The effects of the acquisition will be reflected in the company’s financial statements for the year ending 31 March 2026.

11.	ULTIMATE CONTROLLING PARTY

The company is controlled by its parent entity Ultrahuman Healthcare Private Limited, a company incorporated and registered in India.

In the opinion of the directors, the ultimate controlling party are the directors who hold 100% equity shares in the parent entity.

12.	SHARE BASED PAYMENT ARRANGEMENTS

The company operates an Employee Stock Option Plan (ESOP 2020). The fair value of the options was determined using the Black-Scholes model as at 31 March 2025. The total expense recognised in respect of share-based payment arrangements for the year ended 31 March 2025 amounts to £ 769 (2024: £Nil). The cumulative expense to date is £769, credited to the other reserves account in equity.